Page 90 - Eceptor News Today

A recent Frontiers in Immunology journal study by University of North Carolina at Chapel Hill and Vanderbilt University researchers has created an in vitro system to determine potential therapeutics targeting sensitized effector cells based on human, allergen-specific, Immunoglobulin E (IgE) monoclonal antibodies (mAbs).

Researchers evaluated the efficacy, immunogenicity, and safety of a novel SARS-CoV-2 linear deoxyribonucleic acid vaccine in ferret models delivered using intramuscular injection and electroporation.

Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer.

Researchers investigated the use of aminoadamantane nitrate compounds as anti-SARS-CoV-2 drugs.

Scientists have identified lucidenic acid A, one of the bioactive compounds of Ganoderma lucidum, as a potential inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host cell entry. The study has recently been published in the journal Food and Chemical Toxicology.

The neurohormone oxytocin is well-known for promoting social bonds and generating pleasurable feelings, for example from art, exercise, or sex. But the hormone has many other functions, such as the regulation of lactation and uterine contractions in females, and the regulation of ejaculation, sperm transport, and testosterone production in males.

In a new study, researchers reported severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike (S) protein and S messenger ribonucleic acid (mRNA) nuclear co-translocation as a novel feature of SARS-CoV-2 pathogenesis.

A new study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs.

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.

=Researchers measured the neutralizing titers of plasma samples against the SARS-CoV-2 new variant of concern Omicron's sub-variants BA.4 and BA.5 with arginine (Arg)346 mutations.